TABLE 3.
Percentage change in lipid parameters after 13 weeks of treatment
| Change from baseline lipid parameter (%) | Placebo (N = 11) | Mipomersen (N = 10) |
|---|---|---|
| LDL-C | 1.0 ± 16.5 | −22.0 ± 17.8a |
| VLDL-C | −3.1 ± 24.8 | −13.2 ± 13.8 |
| Non-HDL-C | 0.4 ± 16.3 | −21.3 ± 16.6b |
| HDL-C | 7.5 ± 12.7 | 4.0 ± 9.2 |
| TC | 1.9 ± 14.9 | −16.4 ± 13.4a |
| TG | −7 (−45.9–42.3)c | −16.3 (−35.1–9.8)c |
| Apo A1 | 2.2 ± 12.0 | −1.3 ± 8.6 |
| Apo B | 5.7 ± 13.1 | −19.9 ± 17.4d |
| Lp(a) | 8.0 ± 16.1 | −19.6 ± 14.9d |
Data was analyzed at week 15. Data are presented as the mean ± standard deviation. Apo, apolipoprotein; HDL-C, HDL-cholesterol; LDL-C, LDL-cholesterol; LP(a), lipoprotein (a); TC, total cholesterol TG, triglycerides; VLDL-C, VLDL-cholesterol.
a
P < 0.01 compared with placebo using the Exact Wilcoxon Rank sum test.
b
P < 0.05 compared with placebo using the Exact Wilcoxon Rank sum test.
c
Data are presented as the median (min–max).
d
P < 0.001 compared with placebo using the Exact Wilcoxon Rank sum test.